News
07-06-2010, 05:12 AM
A novel therapy designed to attack tumors in patients with a genetic mutation in either BRCA1 or BRCA2, slowed tumor growth in 85 percent of advanced breast cancer patients treated in a small study, researchers report in the July 6 issue of The Lancet...
More... (http://mnt.to/f/3FLL)
More... (http://mnt.to/f/3FLL)